Mathé G, Amiel J L, Schwarzenberg L, Hayat M, Pouillart P, Schneider M, Cattan A, Jasmin C, Belpomme D, Schlumberger J R, De Vassal F, Musset M, Misset J L
Nouv Presse Med. 1975 May 3;4(18):1337-42.
The authors report a ten year study of active immunotherapy using BCG and irradiated allogeneic leukaemic cells in 200 patients. In acute lymphatic leukaemia, 57 out of 168 patients treated in this way remained in primary remission for 18 months to 10 years after active immunotherapy was begun, the relapse rate became low after 18 months and nil after 36 months. The results varied according to prognostic factors: the cytological type, active immunotherapy being above all effective in small cell (microlymphoblastic and prolymphocytic) types with a hope of cure in 50 to 60 p.cent of cases; malignant cellular volume; meningeal deposits. In microlymphoblastic forms the possibility of survival at the 5th year is greater than 90 p.cent. After relapse during active immunotherapy sensitivity to chemotherapy does not seem to be diminished. Trials of active immunotherapy in acute myeloid leukaemia are worthy of further pursuit. The results of active immunotherapy in leukaemic lymphosarcoma show that immunotherapy may be effective in preventing local recurrence, both of tumour as well as in the marrow. Four patients are in apparently complete remission for more than four years. On the basis of these results, trials of active immunotherapy for "residual disease" should be undertaken in the field of cancerology, going beyond the realm of leukaemias.
作者报告了一项对200例患者使用卡介苗和经辐照的同种异体白血病细胞进行主动免疫治疗的十年研究。在急性淋巴细胞白血病中，168例接受这种治疗的患者中有57例在开始主动免疫治疗后18个月至10年保持初次缓解，18个月后复发率降低，36个月后为零。结果因预后因素而异：细胞学类型，主动免疫治疗在小细胞（微淋巴细胞和原淋巴细胞）类型中最为有效，50%至60%的病例有望治愈；恶性细胞体积；脑膜浸润。在微淋巴细胞型中，第5年的存活可能性大于90%。在主动免疫治疗期间复发后，对化疗的敏感性似乎并未降低。急性髓细胞白血病的主动免疫治疗试验值得进一步探索。白血病性淋巴肉瘤的主动免疫治疗结果表明，免疫治疗在预防肿瘤以及骨髓的局部复发方面可能有效。4例患者明显完全缓解超过4年。基于这些结果，应在肿瘤学领域开展针对“残留疾病”的主动免疫治疗试验，而不仅仅局限于白血病领域。
